Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and bench research with no human clinical trial data reported in the abstract
PubMed 27411588 · doi:10.1016/j.ccell.2016.06.005
What was done
The study evaluated the effects of combining chemotherapy with a fasting-mimicking diet (FMD) in breast cancer and melanoma models. Authors measured bone marrow common lymphoid progenitor cells, CD8+ cytotoxic tumor-infiltrating lymphocytes (TILs), tumor progression, and the role of heme oxygenase-1 (HO-1) downregulation.
What was found
The combination of FMD cycles and chemotherapy increased bone marrow common lymphoid progenitor cells and CD8+ cytotoxic TILs, leading to delayed progression in breast cancer and melanoma. In breast tumors, this effect was mediated in part by downregulating HO-1. The abstract reports qualitative directions and mechanisms but does not report quantitative values, sample sizes, or effect sizes.
Why it matters
This work outlines a mechanistic pathway by which fasting-mimicking diets may augment chemotherapy through immune stimulation and T-cell-mediated tumor cytotoxicity.
Limits
The abstract describes preclinical laboratory models, so findings cannot be directly assumed to apply to human clinical outcomes without human trials. No sample sizes, specific chemotherapy agents, or quantitative metrics are reported in the abstract.
Cited by
- supports Fasting and fasting-mimicking diets increase cytotoxic T-lymphocytes and make cancer cells more exposed and vulnerable to the immune system by counteracting tumor immune-evasion mechanisms.